| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Volume 51(1); 2019 > Article
Kim, Kim, Kang, Chung, Hong, Kim, Song, Lee, Zang, Ko, Song, Baek, Koo, Oh, Cho, and Lee: Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer

Abstract

Purpose

The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).

Materials and Methods

Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.

Results

Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.

Conclusion

This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Introduction

Gastric cancer (GC) is the fifth most common cancer worldwide, and the third leading cause of cancer-related death [1]. It is also the third leading cause of cancer-related death in Korea, where it is the second most common malignancy [2]. Despite progress in cancer therapies, treatment for unresectable or metastatic/recurrent GC remains a significant challenge. Palliative chemotherapy is considered as a cornerstone of treatment for patients with metastatic or recurrent GC [3]. Both quality of life (QOL) and survival have shown improvement as a result of palliative chemotherapy [4,5]. Recently, targeted agents and cancer immunotherapy have led to better outcomes for patients with metastatic or recurrent GC [6,7].
QOL is an exceedingly important issue in the palliative setting. Indeed, a major barrier to palliative chemotherapy is a worry about decreased QOL due to the chemotherapy. Early integration of palliative care has been found to improve QOL and survival in patients with metastatic cancer [8]. However, there is little evidence on the real-world QOL changes during chemotherapy in patients with unresectable or metastatic/recurrent GC.
Korea and Japan both have effective screening programs and clinical practice guidelines for patients with GC [9]. The practice guidelines for palliative chemotherapy are based on evidence collected globally and domestically, and are adopted to harmonize the medical practices within individual countries. Despite the availability of these country-specific clinical practice guidelines, there is still no consensus on a standard chemotherapy for patients with GC, as demonstrated by the global registry of GC treatment evaluation (REGATE) study [10,11]. Specifically, the REGATE study revealed that the disease characteristics and treatment patterns for GC varied across countries.
Therefore, in this prospective observational study, we investigated the chemotherapy patterns and QOL changes during first-line palliative chemotherapy among Korean patients with unresectable or metastatic/recurrent GC.

Materials and Methods

1. Study design and patients

This was a non-interventional, multi-center, prospective, observational study of chemotherapy and QOL in patients with unresectable locally advanced or metastatic/recurrent GC. The formal title of the study is Registry of Chemotherapy and Quality of Life in Unresectable Locally Advanced and Metastatic Gastric Cancer (REQUEST). From September 2010 to December 2012, 532 patients at 26 sites in Korea were enrolled. The inclusion criteria for patients (who were all aged > 20 years) were having histologically confirmed unresectable locally advanced or metastatic/recurrent gastric adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, an expected survival of > 3 months, and no prior palliative chemotherapy for GC. The exclusion criteria were having participated in a clinical trial with any investigational drug within the 30 days prior to study entry or having comorbidities or organ dysfunctions unsuitable for systemic chemotherapy.

2. Data collection and assessment

All the chemotherapy regimens were chosen at the discretion of each medical oncologist. Patient management was conducted in line with the investigator’s medical judgment, given that this was a non-interventional, observational study. Clinical information on the patients, tumor, applied chemotherapy, response to chemotherapy, and survival was collected prospectively. The QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 [12,13]. Patients’ tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors guideline ver. 1.1 [14]. Both the QOL assessment and collection of other data were conducted before the initiation of chemotherapy as well as 3, 6, 9, and 12 months after (±2 weeks). After 12 months, patient survival was followed up by telephone every 3 months up to 24 months.
The QLQ-C30 comprises a single global health status/QOL scale, five functional scales, and nine symptom scales. The QLQ-STO22 comprises 22 items evaluating patients’ disease and treatment-related symptoms, nutritional aspects, and emotional problems. All the scales and single-item measures had scores ranging from 0 to 100, which were the result of standardizing the raw scores via linear transformation. Higher scores indicated a greater response—in other words, a higher score on a functional scale indicates a more healthy level of functioning, a higher score on the global health status/QOL scale indicates a higher QOL, and a higher score on a symptom scale indicates more severe symptomatology or problems.

3. Statistical analysis

Based on the annual report of the Korean National Health Insurance Corporation, there were 90,023 patients with GC in 2008, of which 22,491 were newly diagnosed. Based on this population, we calculated the minimum sample size by applying a 5% margin of error at 95% confidence interval (CI), and using simple random sampling; assuming a 100% response rate, at least 380 patients would be needed for sufficient power. We expected a drop-out rate of at least 10%, so approximate 500 patients were considered as a sufficient sample for this study.
The continuous variables were summarized using descriptive statistics such as the mean, standard deviation, median, and range, whereas categorical variables were summarized using frequencies and percentages. Changes in QOL were determined by subtracting the baseline QOL score from the QOL score measured after treatment, and the results were assessed in line with Osoba et al.’s method [15]: a change of less than 5 points from the baseline was considered as “no change,” a change of 5-10 points was considered “a little,” a change of 11-20 points was considered “moderate,” and a change of greater than 20 was considered “very much.” The difference between baseline and best QOL scores was analyzed using the paired t-test and the Wilcoxon signed rank test. A patient’s overall survival (OS) was defined as the time from enrolment until death, regardless of the cause of death. All patients who were lost to follow up or were alive by the end of the study were censored at the date of their last confirmed survival. We also measured progression-free survival (PFS), which was defined as the time from enrolment until confirmed progressive disease (PD) to first-line palliative chemotherapy or death regardless of cause. Patients who were lost to follow up or who switched to a different chemotherapy without progression to first-line palliative chemotherapy were censored at the last visit date during the firstline palliative chemotherapy. Finally, patients who showed no PD or were not dead at the end of the study were censored at the end-of-study visit. The Kaplan-Meier method was used to analyze the OS and PFS, and the median survival time and 95% CI are reported.

4. Ethical statement

This study was conducted in compliance with the Good Epidemiological Practice guidelines and this report was prepared in accordance with the “strengthening the reporting of observational studies in epidemiology (STROBE)” statement. All patients gave their written informed consent, and the institutional review board at each participating center approved this study.

Results

1. Patient disposition

A total of 532 patients were enrolled. Five of these patients were ultimately excluded because they were participating in other investigational studies, so 527 patients were included in the analysis. The survival and tumor progression of one patient could not be verified; as such, the analyses on PFS and OS were conducted for 526 patients. As of the date of the data cut-off (December 13, 2014), 54.2% (285/526) patients were reported to be alive; the rest were dead.

2. Patients and chemotherapy

The patient characteristics are shown in Table 1. Patients’ median age was 60 years (range, 25 to 86 years) and their median body mass index was 21.0 kg/m2 (range, 14.7 to 33.1 kg/m2). Most patients were male (72.1%) and had an ECOG performance status of 0 or 1 (95.1%). The majority of the patients had a primary tumor location in the body (49.4%) or antrum (43.0%). Of the 527 analyzed patients, 210 (39.9%) had undergone previous gastrectomy.
First-line palliative chemotherapy began in all 527 patients. The changes to second-line palliative chemotherapy at 3, 6, 9, and 12 months are shown in Fig. 1. At 3, 6, 9, and 12 months, 330 (62.6%), 168 (31.9%), 86 (16.3%), and 33 (6.3%) patients, respectively, continued first-line palliative chemotherapy. Of the 527 patients, a total of 195 (37.0%) began second-line palliative chemotherapy over the 12-month study period. The details of the first- and second-line palliative chemotherapy regimens are shown in Table 1. During first-line palliative chemotherapy, combination chemotherapy was more common than monotherapy (93.2% vs. 6.8%, respectively). Of the 491 patients who received combination chemotherapy, the fluoropyrimidine plus platinum doublet regimens were the most common (401/491, 81.7%), and among these regimens, the most popular was 5-fluorouracil plus oxaliplatin and capecitabine plus oxaliplatin. The 36 patients who received monotherapy as their first-line palliative chemotherapy predominately received fluoropyrimidine (22/36, 61.1%).
Although monotherapy was more frequently used as a second-line palliative chemotherapy (36.4%) than as a first-line one (6.8%), combination chemotherapy regimens were still the most popular (63.6%). The most commonly used combination chemotherapy regimens for second-line treatment were irinotecan plus 5-fluorouracil and fluoropyrimidine plus platinum. Among the monotherapy regimens, fluoropyrimidine alone was most frequently used, followed by taxane monotherapy.

3. Efficacy of first-line palliative chemotherapy

During the first-line palliative chemotherapy, tumor response could be evaluated in 385 patients (Table 2). Among these response-evaluable patients, 3.1% (12/385) and 27.0% (104/385) showed a complete response (CR) and a partial response (PR), respectively; therefore, the objective response rate was 30.1% (116/385). In addition, 53.8% (207/385) and 16.1% (62/385) of patients showed stable disease (SD) and PD, respectively. The disease control rate was 83.9% (323/385).
The median OS and PFS following first-line palliative chemotherapy were 14.8 months (95% CI, 13.5 to 16.9) and 8.2 months (95% CI, 7.3 to 8.7), respectively (Fig. 2). A comparison of survival outcomes between patients aged < 70 and ≥ 70 years is shown in Fig. 3; the results showed no difference in either OS or PFS between patients aged < 70 and ≥ 70 years (p=0.884 and p=0.216, respectively). According to the presence of previous gastrectomy history, the median OS and PFS of patients who have undergone gastrectomy were longer than those without gastrectomy (p < 0.001 and p=0.001, respectively) (S1 Fig.).

4. QOL during first-line palliative chemotherapy

The change in QOL during the first-line palliative chemotherapy is shown in Fig. 4 and S2 Table. When using Osoba et al.’s method [15], we observed no “moderate” or “very much” changes (i.e., a change of ≥ 11 points from baseline) in QOL during first-line palliative chemotherapy. “A little” change (5-10 points from baseline) was observed in physical functioning, role functioning, cognitive functioning, global health status, pain, dyspnea, insomnia, appetite loss, constipation, reflux symptoms, dry mouth, taste, body image, and hair loss. The physical, role, and cognitive functioning domains were somewhat worse at certain time points compared to baseline, whereas the other aspects of functioning did not change. Global health status/QOL showed “a little” improvement over the baseline value. As for the symptoms, pain, insomnia, appetite loss, reflux symptoms, and hair loss showed “a little” improvements at some time points during the 12 months. Dyspnea, constipation, dry mouth, taste, body image, and hair loss showed “a little” worsening at some time points.
As for the change in the best QOL scores compared with the baseline during first-line palliative chemotherapy, emotional functioning, social functioning, and global health status/QOL showed “a little” improvements with statistical significance (p < 0.05; Wilcoxon signed-rank test). Additionally, most symptoms showed significant, but "a little" improvements (p < 0.05), except for fatigue, nausea and vomiting, diarrhea, dysphagia, taste, and body image, none of which showed significant alterations (p > 0.05).
We compared changes in QOL during first-line palliative chemotherapy between responders (i.e., patients with CR or PR) and non-responders (patients with SD or PD) (Table 3). When the analysis was conducted in patients who received first-line chemotherapy including all chemotherapy regimens, we found no significant differences in any of the QOL parameters between the two groups (Table 3). When the same analyses were conducted for patients who received oxaliplatin plus fluoropyrimidine (5-fluorouracil or capecitabine) as first-line chemotherapy, eating restrictions by QLQ-STO22 was found to be significantly improved in responders compared with non-responders (S3 Table). In addition, we compared changes in QOL between diseasecontrolled group (i.e., patients with CR, PR, or SD) and disease-uncontrolled group (patients with PD). In patients who received first-line therapy including all chemotherapy regimens, we found that pain and anxiety by QLQ-STO22 were significantly improved in disease-controlled group compared with uncontrolled group (S3 Table). In patients who received oxaliplatin plus fluoropyrimidine as first-line chemotherapy, however, the number of patients who had PD and answered the follow-up QOL questionnaires (in diseaseuncontrolled group) was too small, and thus statistical analysis could not be carried out.

Discussion

This observational study, performed in a real-world setting, provides information on chemotherapy patterns and changes in chemotherapy-related QOL in Korean patients with GC. We found that combination therapy was the most commonly used during first- and second-line palliative chemotherapy. The most common regimen during first-line treatment was fluoropyrimidine plus platinum, which accords with the global treatment pattern for metastatic or recurrent GC [16]. Furthermore, the median PFS and OS after first-line palliative chemotherapy were 8.2 and 14.8 months, respectively. Age did not appear to influence survival outcomes. QOL did not show more than ”a little” change during first-line palliative chemotherapy, and some QOL domains (including various aspects of functioning, global health status/QOL, and symptoms) even showed improvements.
Doublet chemotherapy regimens were evidently preferred for first-line palliative chemotherapy in Korea. A recent retrospective analysis of de-identified patient-level data from medical charts confirmed this, and specified that fluoropyrimidine and platinum agents were most preferred [17]. A meta-analysis of randomized trials by Wagner et al. [18] showed that combination chemotherapy led to significantly better treatment outcomes compared to monotherapy. Several studies have shown that triplet therapy leads to better outcomes in terms of survival and disease response than doublet therapy [18,19]. However, these data need to be carefully interpreted because triplet therapies have also been found to have minimal survival benefit and profoundly increased toxicities compared with doublet therapy [20]. Accordingly, doublet chemotherapy regimens—which provide greater anticancer effects than monotherapy regimens and result in lower toxicity than triplet regimens—are preferred by both the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines over triplet therapies [20]. Therefore, the present study verifies that Korean oncologists appear to follow these guidelines, as they predominantly use fluoropyrimidine plus platinum doublet therapy over monotherapy or triplet therapy as the first-line treatment. Additionally, in our study, oxaliplatin was more commonly used than cisplatin in the fluoropyrimidine plus platinum regimens. Similarly, capecitabine, an oral medication, was more commonly used than intravenous 5-flurouracil. Oxaliplatin plus 5-flurouracil was the most widely used first-line therapy in our study, which accords with the findings of several studies demonstrating the efficacy and safety of oxaliplatin, leucovorin, and 5-flurouracil combination therapy in Korean patients with advanced GC, irrespective of their age, for both first-line and salvage therapy [21,22]. Oxaliplatin plus capecitabine was also widely used, and might have been preferred in cases where 5-flurouracil infusion was inconvenient.
A recent randomized phase III study showed that secondline therapy leads to increased OS when compared to supportive care alone [23,24]. In these phase III studies, a single agent (taxane or irinotecan) was used. While there are no solid data showing that combination chemotherapy is superior to monotherapy in second-line therapy for GC, it is interesting that Korean oncologists still prescribed combination chemotherapy more frequently than monotherapy during the second-line treatment as was found for the first-line treatment. However, the prescription frequency of combination therapy decreased to 63.6% for second-line therapy from the 93.2% for first-line therapy. This is possibly because of the increased number of patients found to be intolerant to combination chemotherapy in the second-line therapy setting.
There is an overall lack of research on QOL in patients with GC treated with first-line palliative chemotherapy in realworld settings, although there have been several previous clinical trials showing that both OS and QOL in patients with advanced GC can be improved via first-line palliative chemotherapy [4,5]. In our study, GC patients were given various chemotherapy agents and we focused on the QOL outcomes thereof. During first-line palliative chemotherapy, we observed no “moderate” or “very much” changes from the baseline. However, global health status/QOL showed maintained or slightly improved scores. Some domains of functioning and symptoms also showed slight improvements. When comparing the best QOL score with the baseline score, we observed that some domains of functioning, global health, and nearly all symptoms showed improvements. These findings indicate that, overall, QOL did not deteriorate in patients with GC during first-line palliative chemotherapy, and was in fact well-maintained.
In addition, when we compared changes in QOL according to tumor response, more improvement in a few QOL parameters was observed in patients whose tumors were shrunk or controlled by palliative chemotherapy than in those whose tumors were not (S3 and S4 Tables). However, changes in most QOL parameters did not significantly differ according to tumor response (Table 3, S3 and S4 Tables). Because we collected the QOL data for first-line chemotherapy every 3 months instead of collecting data at the time point of tumor progression or afterward, most QOL data were gathered while first-line chemotherapy was actively conducted and tumors were well controlled. Therefore, our observation suggests that QOL might be well-maintained regardless of the magnitude of the tumor response if the tumor is effectively controlled by first-line palliative chemotherapy. The changes in QOL might be also different according to the type of administered chemotherapy regimens. In our analyses, the changes in QOL according to tumor response seemed to be a little bit dependent on chemotherapy regimens (all regimens [Table 3] vs. oxaliplatin plus fluoropyrimidine [S3 Table]), although this finding is not conclusive. As sample size in each chemotherapy regimen was not large enough, we could not analyze the changes in QOL per each chemotherapy regimen.
In a previous population-based outcomes study, we identified several barriers for older patients in seeking out highquality medical resources or receiving appropriate treatment. That study showed that age was not an independent prognostic factor for survival in metastatic GC [25]. Furthermore, in older patients with GC, combination chemotherapy might be more effective than monotherapy [26]. Chemotherapy is generally recommended for older cancer patients who have good performance status [27]. In our study, there was no difference in OS or PFS between patients aged < 70 and ≥ 70 years. This finding suggests that older patients with GC who have adequate performance status and medical conditions for receiving chemotherapy will derive roughly the same benefit from first-line palliative chemotherapy as younger patients. In addition, patients with prior gastrectomy had longer OS and PFS than those without gastrectomy. This finding is in accordance with previous studies, which showed the tendency of better prognosis in patients with previous gastrectomy [28,29]. This could be attributed to leadtime bias for early detection of metastatic disease following regular surveillance after radical gastrectomy or different biological characteristics between recurrent disease and initially metastatic disease.
This study has some limitations. First, QOL might differ according to chemotherapy regimens. However, to ensure that the conditions of this study were as realistic as possible, we did not limit the chemotherapy regimens included. Second, participants’ compliance with completing the QOL questionnaires decreased from 95.07% (501/527 patients) to 75.76% (25/33 patients) by the end of the 12-month study period. This trend was similar to the compliance observed for the QLQ-C30 scale in the RAINBOW study [30]. Therefore, patients’ compliance with QOL questionnaires until the end of the observational study should be carefully monitored to assess QOL-related study outcomes. Third, there were no independent reviews of tumor response or disease progression. In addition, tumor evaluation interval using imaging studies was not predefined in this study. These could have influenced the outcome measures. However, we tried to avoid administrative barriers to be able to enroll all patients consecutively because we wanted to represent real-world practice. Lastly, according to the prior use of adjuvant chemotherapy, types of adjuvant chemotherapy regimens and disease-free interval in cases with recurrent GC after curative gastrectomy, the selection of first-line chemotherapy regimens would be different. But, information on adjuvant chemotherapy was not collected in this study.
This study gives some insight into the actual treatment patterns and outcomes among patients with unresectable or metastatic/recurrent GC. By providing data on palliative chemotherapy used in real-world settings in Korea, we hope to improve available guidelines on the treatment of GC. Our study also showed that QOL is well maintained or at least does not deteriorate during first-line palliative chemotherapy. The best QOL scores for most parameters also showed improvement during chemotherapy compared with baseline. This study will help physicians in determining whether chemotherapy will be conducted and which chemotherapy regimens would be selected in patients with advanced GC.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

Conflicts of Interest

This study was sponsored by Sanofi-Aventis Korea Co., Ltd.

Acknowledgments

All authors would like to express our love and gratitude to late Prof. Hong Suk Song who contributed greatly to this study.

Fig. 1.
Study flow chart.
crt-2018-073f1.jpg
Fig. 2.
Overall (A) and progression-free survival (B) of first-line palliative chemotherapy. CI, confidence interval.
crt-2018-073f2.jpg
Fig. 3.
Comparison of overall (A) and progression-free survival (B) of first-line palliative chemotherapy between patients aged < 70 and ≥ 70 years. CI, confidence interval.
crt-2018-073f3.jpg
Fig. 4.
Changes in quality of life domains during first-line palliative chemotherapy. QLQ, Quality of Life Questionnaires; QOL, quality of life.
crt-2018-073f4.jpg
Table 1.
Patient characteristics and administered chemotherapy regimens
Variable No. (%) (n=527)
Age (yr)
 Median (range) 60.0 (25.0-86.0)
 20-39 34 (6.5)
 40-49 70 (13.3)
 50-59 154 (29.2)
 60-69 148 (28.1)
 ≥ 70 121 (23.0)
Sex
 Male 380 (72.1)
 Female 147 (27.9)
ECOG PS
 0 92 (17.5)
 1 409 (77.6)
 2 26 (4.9)
Body mass index
 Median (range) 21.0 (14.7-33.1)
Tumor location (including multiple tumor locations)
 Cardia 57 (10.8)
 Fundus 26 (4.9)
 Body 260 (49.4)
 Antrum 226 (43.0)
 Entire stomach 34 (6.5)
 Unknown 17 (3.2)
Previous operation history
 No 317 (60.2)
 Yes 210 (39.9)
  Total gastrectomy 85 (40.5)a)
  Subtotal gastrectomy 123 (58.6)a)
  Unknown 2 (1.0)a)
First-line palliative chemotherapy regimen
 Monotherapy 36 (6.8)
  Fluoropyrimidine 22 (61.1)b)
  Other agents (taxane, irinotecan, oxaliplatin, etc.) 14 (38.9)b)
 Combination chemotherapy 491 (93.2)
  Fluoropyrimidine plus platinum 401 (81.7)c)
   5-Fluorouracil plus oxaliplatin 169 (34.4)d)
   Capecitabine plus oxaliplatin 148 (30.1)d)
   Capecitabine plus cisplatin 54 (11.0)d)
   S1 plus cisplatin 27 (5.5)d)
   5-Fluorouracil plus cisplatin 3 (0.6)d)
  Trastuzumab plus fluoropyrimidine plus platinum 29 (5.9)c)
  Taxane plus platinum 24 (4.9)c)
  Taxane plus fluoropyrimidine plus platinum 18 (3.7)c)
  Irinotecan plus 5-fluorouracil 10 (2.0)c)
  Other 9 (1.8)c)
Second-line palliative chemotherapy regimen (n=195)
 Monotherapy 71 (36.4)
  Fluoropyrimidine 40 (56.3)e)
  Taxane 18 (25.3)e)
  Irinotecan 8 (11.3)e)
  Other agents 5 (7.0)e)
 Combination chemotherapy 124 (63.6)
  Irinotecan plus 5-fluorouracil 54 (43.5)f)
  Fluoropyrimidine plus platinum 54 (43.5)f)
  Taxane plus platinum 9 (7.3)f)
  Other 7 (5.6)f)

ECOG PS, Eastern Cooperative Oncology Group Scale of Performance Status; S1, tegafur/gimeracil/oteracil.

a) Among patients with previous gastrectomy history,

b) Among monotherapy regimens (first-line),

c) Among combination chemotherapy regimens (first-line),

d) Among fluoropyrimidine plus platinum regimens (first-line),

e) Among monotherapy regimens (second-line),

f) Among combination chemotherapy regimens (second-line).

Table 2.
Best tumor response during first-line palliative chemotherapy
No. (%) (n=385)
Complete response 12 (3.1)
Partial response 104 (27.0)
Stable disease 207 (53.8)
Progressive disease 62 (16.1)
Objective response rate 116 (30.1)
Disease control rate 323 (83.9)
Table 3.
Change in quality of life during first-line palliative chemotherapy in responders (CR or PR) and non-responders (SD or PD)
Responders (CR or PR, n=116)
Non-responders (SD or PD, n=269)
p-valueb)
No. Mean±standard deviation No. Mean±standard deviation
QLQ-C30
 Physical functioning
  Baseline 113 80.53±13.49 250 76.91±18.41
  Best score 93 78.71±16.19 168 74.52±20.02
  Change 92 –1.01±16.51 163 –1.84±20.49 0.985
  p-valuea) 0.589 0.588
 Role functioning
  Baseline 113 80.68±21.54 250 75.13±25.67
  Best score 93 80.65±22.69 168 70.34±28.04
  Change 92 –0.72±26.83 163 –2.15±31.49 0.758
  p-valuea) 0.906 0.251
 Emotional functioning
  Baseline 113 76.77±21.66 250 73.77±21.33
  Best score 93 82.08±20.70 168 79.51±20.29
  Change 92 3.80±24.19 163 8.49±21.78 0.089
  p-valuea) 0.068 < 0.001
 Cognitive functioning
  Baseline 113 85.69±19.40 250 86.00±17.34
  Best score 93 85.30±19.17 168 84.82±19.54
  Change 92 –1.27±21.14 163 –0.61±21.75 0.874
  p-valuea) 0.420 0.397
 Social functioning
  Baseline 113 67.70±32.53 250 70.40±27.77
  Best score 93 76.52±21.46 168 71.33±28.07
  Change 92 8.33±32.26 163 3.17±29.37 0.279
  p-valuea) 0.006 0.038
 Global health status/QOL
  Baseline 113 50.59±23.03 250 51.50±22.90
  Best score 93 60.57±20.60 168 57.14±23.22
  Change 92 10.51±26.75 163 5.62±24.39 0.271
  p-valuea) < 0.001 0.003
 Fatigue
  Baseline 113 34.51±21.94 250 34.76±22.97
  Best score 93 29.99±21.16 168 36.11±21.37
  Change 92 –4.95±23.89 163 0.07±26.09 0.416
  p-valuea) 0.068 0.589
 Nausea and vomiting
  Baseline 113 15.93±20.94 250 18.67±24.19
  Best score 93 15.59±20.53 168 15.48±20.92
  Change 92 –1.27±23.08 163 –4.19±25.95 0.379
  p-valuea) 0.685 0.352
 Pain
  Baseline 113 20.65±20.45 250 25.00±25.05
  Best score 93 15.41±20.15 168 18.25±24.55
  Change 92 –4.53±23.06 163 –6.75±28.12 0.934
  p-valuea) 0.033 0.003
 Dyspnea
  Baseline 113 18.88±21.30 250 15.07±22.55
  Best score 93 14.70±23.29 168 16.67±23.92
  Change 92 –3.62±24.93 163 1.43±27.30 0.114
  p-valuea) 0.223 0.006
 Insomnia
  Baseline 113 23.60±29.44 250 22.93±27.35
  Best score 93 16.49±23.38 168 17.66±27.52
  Change 92 –7.25±33.45 163 –6.95±32.81 0.639
  p-valuea) < 0.001 0.282
 Appetite loss
  Baseline 113 32.15±33.01 250 35.73±34.50
  Best score 93 23.30±28.14 168 30.95±31.08
  Change 92 –8.70±44.44 163 –5.93±41.73 0.577
  p-valuea) 0.050 0.052
 Constipation
  Baseline 113 23.01±30.56 250 22.93±28.78
  Best score 93 15.77±22.30 168 15.87±25.26
  Change 92 –7.25±31.96 163 –9.82±34.33 0.293
  p-valuea) < 0.001 < 0.001
 Diarrhea
  Baseline 113 17.70±27.48 250 18.13±24.82
  Best score 93 12.54±21.37 168 11.31±20.58
  Change 92 –7.25±29.58 163 –5.73±23.89 0.760
  p-valuea) 0.507 0.002
 Financial difficulties
  Baseline 113 34.81±33.74 250 30.00±31.65
  Best score 93 27.60±26.75 168 29.76±30.74
  Change 92 –8.33±33.01 163 –1.64±32.25 0.098
  p-valuea) 0.021 0.498
QLQ-STO22
 Dysphagia
  Baseline 113 13.08±17.52 250 16.44±19.03
  Best score 93 10.39±11.68 168 13.56±16.01
  Change 92 –2.90±18.48 163 –3.89±21.44 0.481
  p-valuea) 0.179 0.083
 Pain
  Baseline 113 26.18±18.99 250 27.17±20.79
  Best score 93 16.04±16.31 168 18.80±19.04
  Change 92 –10.33±18.910 163 –9.51±21.47 0.669
  p-valuea) < 0.001 < 0.001
 Reflux symptoms
  Baseline 113 18.39±18.17 250 18.84±20.73
  Best score 93 12.19±17.65 168 13.62±17.52
  Change 92 –6.52±21.74 163 –6.54±19.97 0.886
  p-valuea) 0.020 < 0.001
 Eating restrictions
  Baseline 113 21.46±18.56 250 24.83±22.15
  Best score 93 14.61±15.43 168 20.49±19.79
  Change 92 –7.88±20.83 163 –6.60±23.40 0.960
  p-valuea) < 0.001 < 0.001
 Anxiety
  Baseline 113 38.05±24.97 250 44.80±25.66
  Best score 93 33.21±23.31 168 39.42±23.63
  Change 92 –3.14±28.88 163 –6.34±27.33 0.203
  p-valuea) 0.468 0.004
 Dry mouth
  Baseline 113 28.61±28.48 250 27.73±27.62
  Best score 93 25.45±25.73 168 25.00±27.48
  Change 92 –3.99±37.58 163 –4.70±32.47 0.838
  p-valuea) 0.152 0.040
 Taste
  Baseline 113 21.53±28.49 250 22.80±28.19
  Best score 93 20.79±24.03 168 21.43±28.56
  Change 92 –1.81±32.16 163 –3.27±34.98 0.376
  p-valuea) 0.676 0.138
 Body image
  Baseline 113 33.92±31.80 250 36.80±32.81
  Best score 93 30.47±30.16 168 36.71±30.44
  Change 92 –2.90±34.11 163 –1.64±35.49 0.768
  p-valuea) 0.432 0.543
 Hair loss
  Baseline 26 48.72±35.57 54 42.59±34.52
  Best score 56 30.36±33.20 103 33.98±28.77
  Change 18 –18.52±44.61 29 ‒2.30±34.42 0.334
  p-valuea) 0.136 0.517

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; QLQ, Quality of Life Questionnaires; QOL, quality of life.

a) Between best score and baseline, Wilcoxon signed rank test,

b) Between responders and non-responders, Kruskal-Wallis test.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
crossref pmid
2. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305.
crossref pmid pmc pdf
3. Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22:2403–14.
crossref pmid pmc
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
crossref pdf
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91.
crossref pmid pmc pdf
6. Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, et al. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol. 2016;34:2728–35.
crossref pmid pmc
7. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.
crossref pmid
8. Nieder C, Norum J. Early palliative care in patients with metastatic non-small cell lung cancer. Ann Palliat Med. 2012;1:84–6.
pmid
9. Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104.
crossref pmid pmc
10. Bang YJ, Yalcin S, Roth A, Hitier S, Ter-Ovanesov M, Wu CW, et al. Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. Asia Pac J Clin Oncol. 2014;10:38–52.
crossref pmid
11. Ter-Ovanesov M, Yalcin S, Zalcberg J, Hitier S, Bang YJ, Wu CW, et al. Registry of gastric cancer treatment evaluation (REGATE): II treatment practice. Asia Pac J Clin Oncol. 2013;9:373–80.
crossref pmid
12. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260–8.
crossref pmid
13. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
crossref pmid pdf
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
crossref pmid
15. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.
crossref pmid
16. Davidson M, Okines AF, Starling N. Current and future therapies for advanced gastric cancer. Clin Colorectal Cancer. 2015;14:239–50.
crossref pmid
17. Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, et al. Real-world treatment patterns among patients with advanced gastric cancer in South Korea. Cancer Res Treat. 2017;49:578–87.
crossref pmid pdf
18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
crossref pmid
19. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
crossref pmid
20. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
pmid
21. Cho YH, Kim SY, Lee MH, Yoo MW, Bang HY, Lee KY, et al. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Gastric Cancer. 2012;15:389–95.
crossref pmid
22. Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat. 2010;42:24–9.
crossref pmid pmc pdf
23. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513–8.
crossref pmid
24. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24:2850–4.
crossref pmid pdf
25. Lee KW, Lee JH, Kim JW, Kim JW, Ahn S, Kim JH. Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. J Cancer Res Clin Oncol. 2016;142:687–97.
crossref pmid pdf
26. Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, et al. A multi-center, open-label, randomized phase III trial of firstline chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017;8:170–5.
crossref pmid
27. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur J Surg Oncol. 2010;36:709–17.
crossref pmid
28. Wang J, Qu J, Li Z, Che X, Zhang J, Liu J, et al. A prognostic model in metastatic or recurrent gastric cancer patients with good performance status who received first-line chemotherapy. Transl Oncol. 2016;9:256–61.
crossref pmid pmc
29. Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, et al. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res. 2012;32:1547–53.
pmid
30. Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016;27:673–9.
crossref pmid pmc pdf
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community